Drug Profile
Research programme: chimeric antigen receptor T cell immunotherapy - Juno Therapeutics
Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Juno Therapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Cancer in USA
- 26 Nov 2019 Early research for cancer is ongoing in USA (Editas Medicine pipeline, November 2019)
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb